Literature DB >> 19552677

How should the patient with multiple endocrine neoplasia type 1 (MEN 1) be followed?

John Burgess1.   

Abstract

Multiple endocrine neoplasia type 1 (MEN 1) is a complex multi-system disease manifesting a diverse range of primary and secondary metabolic and neoplastic disorders. It is possible to improve patient prognosis by early disease detection and treatment. Regular biochemical and radiological screening for parathyroid, gastro-enteropancreatic, pituitary, intrathorasic and adrenal lesions forms the basis of surveillance. The likelihood of adverse sequelea such as renal and bone disease resulting from hyperparathyroidism, severe peptic ulceration and gastric carcinoidosis secondary to hypergastrinaemia can be ameliorated by early detection and management.

Entities:  

Mesh:

Year:  2009        PMID: 19552677     DOI: 10.1111/j.1365-2265.2009.03662.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

Review 1.  Educational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician.

Authors:  Alexis Teplick; Megan Kowalski; Jaclyn A Biegel; Kim E Nichols
Journal:  Eur J Pediatr       Date:  2011-01-06       Impact factor: 3.183

2.  Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1.

Authors:  Grzegorz Piecha; Jerzy Chudek; Andrzej Więcek
Journal:  Int J Endocrinol       Date:  2011-01-17       Impact factor: 3.257

3.  Atypical ovarian carcinoid tumor with widespread skeletal metastases: a case report of multiple endocrine neoplasia type 1 in a young woman.

Authors:  Lei Lou; Lixia Zhou; Wenyan Wang; Huina Li; Yuehong Li
Journal:  BMC Cancer       Date:  2019-11-14       Impact factor: 4.430

4.  p.L105Vfs mutation in a family with thymic neuroendocrine tumor combined with MEN1: a case report.

Authors:  Hongjuan Zheng; Shishi Zhou; Wanfen Tang; Qinghua Wang; Xia Zhang; Xiayun Jin; Ying Yuan; Jianfei Fu
Journal:  BMC Neurol       Date:  2020-03-04       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.